Zoster Eye Disease Study
Status: | Recruiting |
---|---|
Conditions: | Infectious Disease, Ocular |
Therapuetic Areas: | Immunology / Infectious Diseases, Ophthalmology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 1/20/2019 |
Start Date: | August 23, 2017 |
End Date: | December 31, 2020 |
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus
This is a multi-center, randomized, double-masked, placebo-controlled clinical trial of
suppressive valacyclovir for one year in immunocompetent study participants with an episode
of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis
due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment.
suppressive valacyclovir for one year in immunocompetent study participants with an episode
of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis
due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment.
The objective of the Zoster Eye Disease Study (ZEDS) is to determine whether prolonged
suppressive oral antiviral treatment with valacyclovir reduces complications of Herpes Zoster
Ophthalmicus (HZO), thereby improving clinical outcomes in this common and potentially
vision- and life-threatening disease. There are 1,000,000 new cases of Herpes Zoster (HZ) per
year in the USA, with 10-20% being HZO.
Specific AIMS
Primary Aim: The primary aim of this double-masked, placebo controlled multicenter randomized
clinical trial will test the hypothesis that suppressive antiviral treatment for 12 months
with oral valacyclovir 1000 mg daily reduces the rate of new or worsening dendriform
epithelial keratitis, stromal keratitis, endothelial keratitis or iritis compared to placebo,
at 12 months as the primary endpoint, and at 18 months including 6 months of follow-up after
treatment, as a secondary endpoint, in patients with HZO who have had an episode of one of
these disease manifestations during the year prior to enrollment.
Secondary AIM: The second aim is to test the hypothesis that suppressive treatment for 12
months with oral valacyclovir 1000 mg daily reduces the severity and duration of postherpetic
neuralgia (PHN), compared to placebo, at 12 months and at 18 months as secondary endpoints,
in similar patients with HZO. PHN is a debilitating chronic pain syndrome that negatively
impacts quality of life, especially in elderly patients.
The study will enroll immunocompetent patients age 18 years and older who have HZO diagnosed
at variable times in the past, with these types of active anterior segment ocular segment
disease within the past year. Eligible patients will be randomized in a 1:1 ratio to
long-term suppressive treatment with oral valacyclovir 1000 mg daily or placebo for 12
months, plus usual ophthalmic care, and followed every 3 months for a total of 18 months, to
determine outcomes of new or worsening dendriform epithelial keratitis, stromal keratitis,
endothelial keratitis or iritis and/or severity and duration of PHN during 12 months of
treatment and for 6 months following treatment discontinuation. The results with regard to
PHN may be applicable to HZ in other locations. If suppressive valacyclovir treatment is
determined to be effective, the potentially devastating disease burden of HZO and HZ may be
reduced for patients, as well as the annual costs to society, estimated in the USA to be one
billion dollars.
suppressive oral antiviral treatment with valacyclovir reduces complications of Herpes Zoster
Ophthalmicus (HZO), thereby improving clinical outcomes in this common and potentially
vision- and life-threatening disease. There are 1,000,000 new cases of Herpes Zoster (HZ) per
year in the USA, with 10-20% being HZO.
Specific AIMS
Primary Aim: The primary aim of this double-masked, placebo controlled multicenter randomized
clinical trial will test the hypothesis that suppressive antiviral treatment for 12 months
with oral valacyclovir 1000 mg daily reduces the rate of new or worsening dendriform
epithelial keratitis, stromal keratitis, endothelial keratitis or iritis compared to placebo,
at 12 months as the primary endpoint, and at 18 months including 6 months of follow-up after
treatment, as a secondary endpoint, in patients with HZO who have had an episode of one of
these disease manifestations during the year prior to enrollment.
Secondary AIM: The second aim is to test the hypothesis that suppressive treatment for 12
months with oral valacyclovir 1000 mg daily reduces the severity and duration of postherpetic
neuralgia (PHN), compared to placebo, at 12 months and at 18 months as secondary endpoints,
in similar patients with HZO. PHN is a debilitating chronic pain syndrome that negatively
impacts quality of life, especially in elderly patients.
The study will enroll immunocompetent patients age 18 years and older who have HZO diagnosed
at variable times in the past, with these types of active anterior segment ocular segment
disease within the past year. Eligible patients will be randomized in a 1:1 ratio to
long-term suppressive treatment with oral valacyclovir 1000 mg daily or placebo for 12
months, plus usual ophthalmic care, and followed every 3 months for a total of 18 months, to
determine outcomes of new or worsening dendriform epithelial keratitis, stromal keratitis,
endothelial keratitis or iritis and/or severity and duration of PHN during 12 months of
treatment and for 6 months following treatment discontinuation. The results with regard to
PHN may be applicable to HZ in other locations. If suppressive valacyclovir treatment is
determined to be effective, the potentially devastating disease burden of HZO and HZ may be
reduced for patients, as well as the annual costs to society, estimated in the USA to be one
billion dollars.
PARTICIPANT INCLUSION CRITERIA
To be eligible for study participation, an individual must meet all of the following
criteria:
1. Ability to understand, and willingness and ability to read and sign, the informed
consent form.
2. Ability to understand and follow instructions and study procedures.
3. Willingness to comply with all study procedures and be available for the duration of
the study.
4. Ability to take oral medication, and are willing to adhere to study medication
regimen.
5. Age 18 years or older.
6. Diagnosed with HZO in one eye based on both of these criteria:
1. History of characteristic unilateral, usually vesicular, rash in the dermatomal
distribution of cranial nerve V1.
2. Medical record documentation of an episode of active dendriform epithelial
keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to HZO
within the preceding year. This episode of active anterior segment ocular disease
may be due to HZO of recent onset (within the preceding 6 months); or chronic HZO
(with onset six or more months ago); may be new, worsening, or recurrent disease
after a period of inactivity; and may occur after medication was reduced.
i. Study participants with chronic HZO must be on a stable treatment regimen and off
antivirals for at least 30 days before enrollment. Study participants with chronic HZO
who do not meet this criterion may be rescreened, if they are able to meet this
criterion within 3 months after the study visit. (This is not a requirement for study
participants with recent onset HZO, who may be enrolled at any time, preferably after
completing recommended acute antiviral treatment, if prescribed, is completed).
7. For females with reproductive potential, willingness to use highly effective
contraception (e.g., hormonal contraception, barrier contraception, intrauterine
device, or abstinence).
PARTICIPANT EXCLUSION CRITERIA
An individual who meets any of the following criteria will be excluded from participation
in this study:
1. History of immunocompromised status as defined by current CDC contraindications for
the vaccine against zoster (44).
1. Study participants who are diagnosed with leukemia, lymphomas or other malignant
neoplasms affecting bone marrow or lymphatic system, unless leukemia in remission
and off chemotherapy for at least 3 months.
2. Study participants who are diagnosed with Acquired Immune Deficiency Syndrome
(AIDS) or presents with other clinical manifestations of Human Immunodeficiency
virus (HIV) including CD4 count of ≤ 200 cells/ml.
3. Study participants on immunosuppressive therapy including:
i. High-dose corticosteroids (greater than equivalent of prednisone 20 mg/day within 1
month) ii. Chemotherapy, other than low dose used for treatment of immune-mediated
diseases within 3 months iii. Study participants receiving recombinant human immune
mediators and immune modulators, especially antitumor necrosis agents, within 1 month
prior to enrollment d. Study participants with unspecified cellular immunodeficiency.
e. Study participants with history of hematopoietic stem cell transplantation.
2. Medical history of a systemic disease and thought likely to meet one of the exclusion
criteria listed in exclusion criterion #1 during the 18-month study period.
3. Renal insufficiency:
1. Requires dialysis or has history of renal transplant or
2. eGFR less than 45, determined within 30 days preceding enrollment.
4. Allergy or adverse reaction to valacyclovir or acyclovir.
5. History of vaccination against zoster within one month prior to enrollment. Study
participants who meet this exclusion criterion may be rescreened. If the study
participant receives the Herpes Zoster Subunit vaccine (Recombinant Zoster Vaccine
(RZV), Shingrix), rescreening should take place one month after the second required
dose of the vaccine.
6. Keratorefractive surgery, other than limbal relaxing incisions or astigmatic
keratotomies at the time of cataract surgery, within 5 years of enrollment, or
keratoplasty of the involved eye with zoster.
7. On systemic antivirals with activity against herpes within the past 30 days, including
acyclovir, valacyclovir, or famciclovir, for any reason except for treatment of acute
HZO, including investigational drug trial.
8. History of another condition that may require treatment with one of these three
antivirals listed above in exclusion criterion #7, during the course of the study;
study participants who require chronic suppressive antiviral treatment with these
medications will be excluded.
9. Sexually active women who are pregnant, nursing, or in their reproductive years who do
not agree to use contraception during the 1-year treatment period.
10. Incarceration
11. Any condition or circumstance that in the opinion of the study investigator, would
place the study participant in increased risk or affect his/her full compliance or
completion of the study.
12. Participation in a clinical study testing a drug, biologic, device or other
intervention within the last 30 days from enrollment visit. Study participants who
meet this criterion may be rescreened.
We found this trial at
60
sites
1 Medical Center Dr
Lebanon, New Hampshire 03756
Lebanon, New Hampshire 03756
(603) 650-5000
Principal Investigator: Donald Miller, MD
Phone: 603-650-0556
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
Birmingham, Alabama 35233
(205) 934-4011
Principal Investigator: Priscilla Fowler, MD
Phone: 205-488-0777
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
Boston, Massachusetts 02111
(617) 636-5000
Principal Investigator: Kenneth R Kenyon, MD
Phone: 617-636-1051
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
Durham, North Carolina 27710
(919) 684-8111
Principal Investigator: Melissa Daluvoy, MD
Phone: 919-681-8872
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Sonal Tuli, MD
Phone: 352-373-8787
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Shahzad Mian, MD
Phone: 734-647-8397
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Ronald Wise, MD
Phone: 720-848-2035
Click here to add this to my saved trials
Bala-Cynwyd, Pennsylvania 19004
Principal Investigator: Irving M Raber, MD
Phone: 484-434-2706
Click here to add this to my saved trials
Baltimore, Maryland 20742
(301) 405-1000
Principal Investigator: Wuqaas Munir, MD
Phone: 667-214-1161
University of Maryland As a globally-connected university offering a world-class education, the University of Maryland...
Click here to add this to my saved trials
Baltimore, Maryland 21215
Principal Investigator: Laura Green, MD
Phone: 410-601-7643
Click here to add this to my saved trials
Bethesda, Maryland 20817
Principal Investigator: Divya Srikumaran, MD
Phone: 240-482-1108
Click here to add this to my saved trials
Bloomington, Minnesota 55431
Principal Investigator: Sherman Reeves, MD
Phone: 952-567-6111
Click here to add this to my saved trials
243 Charles St
Boston, Massachusetts 02114
Boston, Massachusetts 02114
(617) 523-7900
Principal Investigator: James Chodosh, MD
Phone: 617-573-6823
Massachusetts Eye & Ear Infirmary Whether you see our physicians at Mass. Eye and Ear's...
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Hyunjoo Lee, MD
Phone: 617-414-8848
Click here to add this to my saved trials
Canandaigua, New York 14424
Principal Investigator: Holly Hindman, MD
Phone: 585-391-1181
Click here to add this to my saved trials
1200 West Harrison Stree
Chicago, Illinois 60607
Chicago, Illinois 60607
(312) 996-4350
Principal Investigator: Joel Sugar, MD
Phone: 312-996-7204
Univ of Illinois A major research university in the heart of one of the world's...
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Kavitha Sivaraman, MD
Phone: 513-569-3462
Click here to add this to my saved trials
Cleveland, Indiana 44106
Principal Investigator: Pankaj Gupta, MD
Phone: 216-844-8552
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216-368-2000
Principal Investigator: Pankaj Gupta, MD
Phone: 216-844-8552
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
Click here to add this to my saved trials
Dallas, Texas 75231
Principal Investigator: Gregory Nettune, MD
Phone: 214-696-5900
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: James McCulley, MD
Phone: 214-645-2012
Click here to add this to my saved trials
Danville, Pennsylvania 17822
Principal Investigator: Herbert Ingraham, MD
Phone: 570-214-6070
Click here to add this to my saved trials
Delray Beach, Florida 33484
Principal Investigator: Steven I Rosenfeld, MD
Phone: 561-498-8100
Click here to add this to my saved trials
East Setauket, New York 11733
Principal Investigator: Azin Abazari, MD
Phone: 631-444-4090
Click here to add this to my saved trials
Glenview, Illinois 60026
Principal Investigator: Marian Macsai, MD
Phone: 847-657-1750
Click here to add this to my saved trials
Golden Valley, Minnesota 55427
Principal Investigator: John Berestka, MD
Phone: 763-383-4140
Click here to add this to my saved trials
Grand Rapids, Michigan 49546
Principal Investigator: Ann M Renucci, MD
Phone: 616-949-2001
Click here to add this to my saved trials
Great Neck, New York 11021
Principal Investigator: Anne Steiner, MD
Phone: 516-881-7046
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Alice Matoba, MD
Phone: 713-798-4123
Click here to add this to my saved trials
Indianapolis, Indiana 46260
Principal Investigator: Francis Price, Jr., MD
Phone: 317-814-2996
Click here to add this to my saved trials
Lexington, Kentucky
859) 257-9000
Principal Investigator: Douglas G Katz, MD
Phone: 859-323-5868
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
Click here to add this to my saved trials
Littleton, Colorado 80120
Principal Investigator: Stephen L Forstot, MD
Phone: 720-709-7533
Click here to add this to my saved trials
Loma Linda, California 92354
Principal Investigator: Frank Huang, MD
Phone: 909-558-2168
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Gary N Holland, MD
Phone: 310-825-5440
Click here to add this to my saved trials
Madison, Wisconsin 53706
(608) 263-2400
Principal Investigator: Sarah Nehls, MD
Phone: 608-262-6222
University of Wisconsin-Madison In achievement and prestige, the University of Wisconsin-Madison has long been recognized...
Click here to add this to my saved trials
Miami, Florida
Principal Investigator: Guillermo Amescua, MD
Phone: 305-326-6508
Click here to add this to my saved trials
261 James Street
Morristown, New Jersey 07960
Morristown, New Jersey 07960
Principal Investigator: Marta Lopatynsky, MD
Phone: 973-984-3937
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Uyen Tran, MD
Phone: 615-936-1639
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Mark D Ewald, MD
Phone: 615-320-7200
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Principal Investigator: Jayne S Weiss, MD
Phone: 504-568-7634
Click here to add this to my saved trials
462 1st Avenue
New York, New York 10010
New York, New York 10010
Principal Investigator: Ilyse Haberman, MD
Phone: 646-501-9883
Click here to add this to my saved trials
1305 York Avenue
New York, New York 10021
New York, New York 10021
Principal Investigator: Jessica Ciralsky, MD
Phone: 646-962-4118
Click here to add this to my saved trials
New York, New York
Principal Investigator: David Ritterband, MD
Phone: 212-979-4251
Click here to add this to my saved trials
Owings Mills, Maryland 21117
Principal Investigator: Marc A Hinig, MD
Phone: 410-581-1500
Click here to add this to my saved trials
Peabody, Massachusetts 02149
Principal Investigator: Sarkis H Sarkiasian, MD
Phone: 978-538-4412
Click here to add this to my saved trials
840 Walnut Street
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19107
Principal Investigator: Kristin Hammersmith, MD
Phone: 215-928-3180
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Steven Orlin, MD
Phone: 215-662-8091
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
Portland, Oregon 97239
Principal Investigator: John Clements, MD
Phone: 503-494-0482
Click here to add this to my saved trials
Portland, Oregon 97210
Principal Investigator: Michael Straiko, MD
Phone: 503-413-6937
Click here to add this to my saved trials
Richmond, Virginia 23226
Principal Investigator: Christonpher Estopinal, MD
Phone: 804-287-4219
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Keith Baratz, MD
Phone: 507-538-8119
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Andrew Jing-Wei Huang, MD
Phone: 314-747-5832
Click here to add this to my saved trials
Salt Lake City, Utah 84132
Principal Investigator: Amy Lin, MD
Phone: 801-585-6647
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: Charles Reilly, MD
Phone: 210-424-2584
Click here to add this to my saved trials
San Francisco, California 94131
Principal Investigator: John Gonzales, MD
Phone: 979-229-4895
Click here to add this to my saved trials
San Luis Obispo, California 93401
Principal Investigator: Mark D Sherman, MD
Phone: 805-503-1016
Click here to add this to my saved trials
Seattle, Washington 98101
(888) 862-2737
Principal Investigator: Henry Geggel, MD
Phone: 206-342-6976
Virginia Mason Medical Center Established in 1920, Virginia Mason began as an 80-bed hospital with...
Click here to add this to my saved trials
Towson, Maryland 21204
Principal Investigator: Angelique Pillar, MD
Phone: 410-616-9953
Click here to add this to my saved trials
Walnut Creek, California 94598
Principal Investigator: Mira Lim, MD
Phone: 925-947-0888
Click here to add this to my saved trials
Washington, District of Columbia 20007
Principal Investigator: Aruoriwo Oboh-Weilke, MD
Phone: 202-444-7237
Click here to add this to my saved trials